Skip to content

US · NCEL · BIOTECHNOLOGY

NewcelX Ltd. (NCEL) intrinsic value and stock valuation

$2.54as of 2026-11-21 · Mkt cap 1.6M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NewcelX Ltd. DCF and intrinsic value

InvestorsCraft values NCEL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NCEL’s statements →

NewcelX Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Kloten, ZH 8058 newcelx.net

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-8.3M
20172025
Free cash flow
-$-2.77M
20172025
Total equity
$7.25M
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-2.47M-$-4.38M-$-11.81M-$-15.48M-$-11.86M
Net income-$-8.3M-$-1.98M-$-12.17M-$-16.5M-$-11.95M
EPSd-$-2.16M-$-13.2M-$-3.19M-$-8.38M-$-8.13M
Operating cash flow-$-2.77M-$-4.27M-$-9.68M-$-13.88M-$-14.94M
Capital expenditure-$-10K-$0.00-$0.00$0.00-$-40K
Free cash flow-$-2.77M-$-4.27M-$-9.68M-$-13.88M-$-14.98M
Total assets$11.5M$2.23M$1.85M$9.28M$5.76M
Total debt$350K$0.00$1.63M$0.00$0.00
Net debt-$-1.85M-$-1.67M$740K-$-8.95M-$-5.43M
Total equity$7.25M$1.41M-$-8.83M$3.28M$540K
Cash and short-term investments$2.2M$1.67M$900K$8.95M$5.43M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$10K$10K$10K
Gross profit$0.00-$0.00-$-10K-$-10K-$-10K
Research and development expenses$1.13M$420K$5.91M$8.98M$5.92M
Selling, general and administrative expenses$1.35M$3.21M$5.9M$6.49M$5.93M
Other expenses$0.00$740K$0.00$0.00$0.00
Operating expenses$2.47M$4.38M$11.8M$15.5M$11.9M
Cost and expenses$2.47M$4.38M$11.8M$15.5M$11.9M
Interest income$370K$0.00$0.00$0.00$0.00
Interest expense$6.01M$150K$150K$100K$70K
Depreciation and amortization$60K$0.00$10K$10K$10K
Ebitda-$-2.24M-$-3.63M-$-11.8M-$-15.47M-$-11.85M
Operating income-$-2.47M-$-4.38M-$-11.81M-$-15.48M-$-11.86M
Total other income/expenses, net-$-5.83M$2.4M-$-360K-$-1.01M-$-90K
Income before tax-$-8.3M-$-1.98M-$-12.17M-$-16.5M-$-11.95M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-8.3M-$-1.98M-$-12.17M-$-16.5M-$-11.95M
Weighted average shares outstanding$3.84M$80K$3.82M$1.97M$1.47M
Weighted average diluted shares outstanding$3.84M$150K$3.82M$1.97M$1.47M
Balance sheet
20252024202320222021
Cash and short-term investments$2.2M$1.67M$900K$8.95M$5.43M
Net receivables$0.00$400K$10K$40K$40K
Inventory$0.00$0.00$0.00-$-40K-$-40K
Total current assets$3.18M$2.23M$1.82M$9.25M$5.72M
Property, plant and equipment, net$100K$10K$10K$20K$30K
Goodwill and intangible assets$8.17M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$8.26M$10K$20K$30K$40K
Total assets$11.5M$2.23M$1.85M$9.28M$5.76M
Accounts payable$1.92M$520K$4.63M$2.37M$1.74M
Short-term debt$350K$0.00$1.63M$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.2M$830K$7.92M$3.36M$2.4M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$2.5M$2.5M$2.5M
Total non-current liabilities$0.00$0.00$2.76M$2.64M$2.82M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$4.2M$830K$10.7M$6M$5.22M
Common stock$290K$170K$730K$670K$340K
Retained earnings-$-84.89M-$-74.43M-$-70.37M-$-58.2M-$-41.71M
Accumulated other comprehensive income (loss)-$-1.84M$110K-$-160K-$-50K-$-150K
Total equity$7.25M$1.41M-$-8.83M$3.28M$540K
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$350K$0.00$1.63M$0.00$0.00
Net debt-$-1.85M-$-1.67M$740K-$-8.95M-$-5.43M
Cash flow statement
20252024202320222021
Net income-$-8.3M-$-1.98M-$-12.17M-$-16.5M-$-11.95M
Depreciation and amortization$60K$0.00$10K$10K$10K
Stock-based compensation$770K$130K$160K$20K$0.00
Change in working capital-$-1.07M$80K$2.25M$1.63M-$-3.17M
Accounts receivable$0.00$0.00$0.00$0.00-$-20K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-870K-$-120K$2.26M$640K-$-2.27M
Net cash provided by operating activities-$-2.77M-$-4.27M-$-9.68M-$-13.88M-$-14.94M
Investments in property, plant and equipment-$-10K-$0.00-$0.00$0.00-$-40K
Acquisitions, net$1.71M$0.00$0.00$0.00$0.00
Net cash used for investing activities$1.7M-$0.00$0.00-$-3.51M-$-40K
Common stock issued$2.34M$5.25M$0.00$9.22M$14.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.63M$5.04M$1.63M$17.4M$20.3M
Net change in cash$1.55M$770K-$-8.05M$3.52M$5.34M
Cash at end of period$2.2M$1.67M$900K$8.95M$5.43M
Operating cash flow-$-2.77M-$-4.27M-$-9.68M-$-13.88M-$-14.94M
Capital expenditure-$-10K-$0.00-$0.00$0.00-$-40K
Free cash flow-$-2.77M-$-4.27M-$-9.68M-$-13.88M-$-14.98M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NewcelX Ltd.

        NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.

        CEO
        Ronen Twito
        Employees
        11
        Beta
        0.93

        Explore

        Frequently asked questions

        What is the intrinsic value of NewcelX Ltd. (NCEL)?

        InvestorsCraft does not currently publish an intrinsic value for NCEL. How the IC value is calculated.

        Is NCEL undervalued?

        InvestorsCraft does not publish an undervaluation signal for NCEL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.